Dr. Henry C Fung is a distinguished figure in the fields of hematology and oncology, renowned for his extensive research and clinical contributions, particularly in hematopoietic stem cell transplantation and lymphoma treatment. His work has significantly advanced our understanding and treatment of complex hematologic malignancies and has offered new hope to countless patients. This article delves into the impactful career of Dr. Fung, highlighting his key publications and the breadth of his expertise.
Dr. Fung’s research spans a wide range of critical areas within hematology and oncology, with a pronounced focus on improving outcomes for patients undergoing hematopoietic stem cell transplantation. His publications reflect a deep commitment to tackling the challenges associated with these complex procedures, from managing side effects to optimizing treatment regimens and addressing psychological factors impacting patient recovery.
One significant area of Dr. Fung’s research is lymphoma, particularly primary mediastinal B cell lymphoma and primary central nervous system lymphoma. His contributions in this domain are evident in publications such as “Primary Mediastinal B Cell Lymphoma,” and “Primary Central Nervous System Lymphoma,” indicating his expertise in understanding and treating these specific lymphoma subtypes. These works are crucial for clinicians seeking the most up-to-date knowledge in managing these challenging conditions.
Further underscoring his lymphoma expertise is the publication, “Sequential single-agent obatoclax mesylate (GX15-070MS) followed by combination with rituximab in patients with previously untreated follicular lymphoma.” This study explores innovative treatment strategies for follicular lymphoma, a common type of non-Hodgkin lymphoma, demonstrating Dr. Fung’s dedication to improving therapeutic approaches and patient outcomes in lymphoma.
Beyond lymphoma, Dr. Fung has made substantial contributions to the field of hematopoietic stem cell transplantation. His research addresses various facets of transplantation, aiming to refine protocols and enhance patient care. “Gastrointestinal Side Effects and Adequacy of Enteral Intake in Hematopoietic Stem Cell Transplant Patients” highlights his concern for managing the nutritional and gastrointestinal challenges faced by transplant recipients. This patient-centered approach is also evident in “Anger, provider responses, and pain: Prospective analysis of stem cell transplant patients,” and “Posttraumatic stress symptoms predict impaired neutrophil recovery in stem cell transplant recipients,” which explore the psychological dimensions of stem cell transplantation, recognizing the importance of holistic patient care.
Dr. Fung’s work also delves into the practical aspects of stem cell transplantation, seeking to optimize treatment delivery and efficacy. “Evaluating Neutropenia Recovery in Patients Receiving Filgrastim on Day+ 5 Versus Day+ 10 Post Autologous Hematopoietic Stem Cell Transplant” investigates strategies to improve neutrophil recovery, a critical factor in preventing infections post-transplant. His research extends to optimizing drug administration in transplant settings, as seen in “Dosing Algorithm for Concomitant Administration of Sirolimus, Tacrolimus, and an Azole After Allogeneic Hematopoietic Stem Cell Transplantation,” aiming to refine medication protocols for better patient management.
Furthermore, Dr. Fung’s research explores innovative approaches to enhance the effectiveness of cellular therapies. “CD26 Protease Inhibition Improves Functional Response of Un-fractionated Mobilized Peripheral Blood Mononuclear Cells to CXCL12/SDF-1” exemplifies his investigation into cutting-edge techniques to improve transplant efficiency and outcomes at a cellular level. His case report, “High-Dose Chemotherapy with Autologous Stem Cell Rescue for Relapse after Allo-SCT in Multiple Myeloma: A Case Report,” showcases his expertise in managing complex cases, such as relapse after allogeneic stem cell transplantation in multiple myeloma.
Dr. Fung’s earlier work also includes significant clinical trials and investigations into novel treatment regimens. “Phase II trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients with Non-Hodgkin’s Lymphoma” and “Tandem Autologous Stem Cell Transplantation for Patients with Primary Refractory or Poor Risk Recurrent Hodgkin Lymphoma” demonstrate his pioneering efforts in exploring and establishing effective treatment strategies for various hematologic malignancies. His research also extends to the realm of multiple myeloma, with publications like “Maintenance Thalidomide Following Single Cycle Autologous Peripheral Blood Stem Cell Transplant in Patients with Multiple Myeloma,” and “Induction Chemotherapy Before Autologous Stem Cell Transplantation for Patients with Symptomatic Plasma Cell Myeloma—-does it matter?” contributing to the refinement of treatment protocols for this challenging disease.
In conclusion, Dr. Henry C Fung’s extensive body of work underscores his position as a leading expert in hematopoietic stem cell transplantation and oncology. His publications are a testament to his dedication to advancing the field, improving patient outcomes, and pushing the boundaries of knowledge in hematologic malignancies. His research provides invaluable insights for clinicians and researchers alike, solidifying his legacy as a significant contributor to the fight against cancer and related diseases.
References:
- Syed A. Abutalib, Kieron Dunleavy & Henry C. Fung: Primary Mediastinal B Cell Lymphoma. In Clinical Oncology (In Press).
- Henry C Fung, Philip Pancari and Patricia Kropf. Primary Central Nervous System Lymphoma. In Clinical Manual of Blood & Marrow Hematopoietic Cell Transplantation. Edited by Dr. Syed A. Abutalib & Dr. Parameswaran Hari (In Press).
- A Goy, M Berger, P Ford, T Feldman, A Mato, C Bejot and Henry C Fung – Leukemia & lymphoma, 2014/12. Sequential single-agent obatoclax mesylate (GX15-070MS) followed by combination with rituximab in patients with previously untreated follicular lymphoma.: PubMed
- M Walrath, C Bacon, S Foley, HC Fung – Nutrition in Clinical Practice, 2014/9. Gastrointestinal Side Effects and Adequacy of Enteral Intake in Hematopoietic Stem Cell Transplant Patients: PubMed
- JI Gerhart, V Sanchez Varela, JW Burns, SE Hobfoll, HC Fung; Health Psychology 34 (3), 197. Anger, provider responses, and pain: Prospective analysis of stem cell transplant patients: PubMed
- SE Hobfoll, JI Gerhart, AK Zalta, K Wells, J Maciejewski and Henry C Fung- Psycho‐Oncology, 2015. Posttraumatic stress symptoms predict impaired neutrophil recovery in stem cell transplant recipients: PubMed
- LM DiGrazia, M Janusek, K Schultz, L Geswein, HC Fung; Journal of Oncology Pharmacy Practice (in press). Evaluating Neutropenia Recovery in Patients Receiving Filgrastim on Day+ 5 Versus Day+ 10 Post Autologous Hematopoietic Stem Cell Transplant.
- Peksa GD, Schultz K, Fung HC: Dosing Algorithm for Concomitant Administration of Sirolimus, Tacrolimus, and an Azole After Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Oncology Pharmacy Practice. 2014 June 17: pii:1078155214539625. [Epub ahead of print]. PubMed
- Christopherson KW 2nd, Frank R, Jagan S, Paganessi LA, Rizman A, Gezer S, Gregory SA, Fung HC: CD26 Protease Inhibition Improves Functional Response of Un-fractionated Mobilized Peripheral Blood Mononuclear Cells to CXCL12/SDF-1. Exp Hematol 2012 Nov;40(11):945-52.doi:10.1016/j.exphem.2012.07.009. Epub 2012 Jul 27. PubMed
- Tuncer HH, Gregory SA, Fung HC: High-Dose Chemotherapy with Autologous Stem Cell Rescue for Relapse after Allo-SCT in Multiple Myeloma: A Case Report. Bone Marrow Transplant Oct 2010. PubMed
- Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D, Rodriguez R, Spielberger RT, Falk P, Palmer JM, Forman SJ: Phase II trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients with Non-Hodgkin’s Lymphoma. Journal of clinical Oncology 2008 Jan 1;26(1):90-5. Epub 2007 Nov 19. PubMed
- Fung HC, Stif P, Schriber J, Toor A, Smith E, Rodriguez T, Krishnan A, Molina A, Smith D, Ivers, Kogut N, Popplewell L, Rodriguez R, Somlo G, Forman SJ, Nademanee A:. Tandem Autologous Stem Cell Transplantation for Patients with Primary Refractory or Poor Risk Recurrent Hodgkin Lymphoma. Biol Blood Marrow Transplant 2007 May;13(5):594-600. Epub 2007 Mar 23. PubMed
- Sahebi F, Spielberger R, Kogut NM, Fung HC, et al.: Maintenance Thalidomide Following Single Cycle Autologous Peripheral Blood Stem Cell Transplant in Patients with Multiple Myeloma. Bone Marrow Transplantation 2006 May;37(9):825-9. PubMed
- Henry C Fung MBchB, FRCPE, Sunita Nathan MD, John J Maciejewski MD, PhD: Induction Chemotherapy Before Autologous Stem Cell Transplantation for Patients with Symptomatic Plasma Cell Myeloma—-does it matter? Clinical Pharmacology: Advances and Applications (2010). PubMed
- A.M. Jimenez, Henry C Fung and Kent Chistopherson II: Strategies for Improving Transplant Efficiency in the Context of Cellular Therapeutics. Transfusion 2011 Nov; 51 Suppl 4: 125S-137S. doi: 10.1111/j. 1537-2995.2001.03375.x. PubMed
